Research programme: Huntington's disease therapeutics - Provid Pharmaceuticals/Duke University
Latest Information Update: 20 Nov 2007
At a glance
- Originator Duke University Medical Center; Provid Pharmaceuticals
- Class Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 19 Aug 2003 Preclinical trials in Huntington's disease in USA (unspecified route)